Anti-TACA Antibodies | Tumor-Associated Carbohydrate Antigens

Discover anti-TACA antibodies targeting tumor-associated carbohydrate antigens overexpressed on cancer cell surfaces. Aberrant glycosylation is a hallmark of malignant transformation: oncogenic signaling reprograms glycosyltransferase expression, leading to truncated O-glycans (Tn, sialyl-Tn/sTn, Thomsen-Friedenreich/TF antigen), neo-expressed glycosphingolipids (Globo H, SSEA-3/4, Lewis Y/X), and overexpressed gangliosides (GD2, GD3, GM2, fucosyl-GM1, polysialic acid) that are absent or minimally expressed on normal adult tissues. These TACAs serve as both diagnostic biomarkers and therapeutic targets, with anti-GD2 (dinutuximab) already FDA-approved for neuroblastoma and multiple anti-Globo H and anti-sTn candidates in clinical development. Our panel covers Globo-series glycolipids, Lewis blood group antigens, truncated mucin-type O-glycans, and gangliosides — supporting cancer glycobiology mechanistic studies, carbohydrate-based vaccine development and immunogenicity monitoring, glycan-targeted immunotherapy (ADCC, CDC, ADC payload delivery), TACA expression profiling for patient stratification, and glycan microarray-based epitope mapping. RUO

Broad TACA Panel Comprehensive coverage across all major TACA families: Globo-series (Globo H, SSEA-3, SSEA-4), Lewis antigens (Le^Y, Le^X, sLe^A), truncated O-glycans (Tn, sTn, TF antigen), and gangliosides (GD2, GD3, GM2, fucosyl-GM1, polysialic acid). Multiple clones per target enable epitope-level discrimination and competitive binding studies.

Glycan Specificity Validated Binding specificity confirmed via glycan microarray screening, competitive ELISA with free glycan inhibitors, and flow cytometry on glycan-expressing and glycosyltransferase-knockout cell lines. Cross-reactivity profiles with structurally related glycans are documented on each product datasheet.

Cancer Immunotherapy Research Anti-GD2 (dinutuximab analog), anti-Globo H, and anti-Lewis Y reference antibodies for ADCC, CDC, and antibody-drug conjugate (ADC) payload delivery studies. Support mechanism-of-action investigation, Fc engineering optimization, and glycan-targeted bispecific antibody development.

Glycan Vaccine Development Detect anti-glycan IgG/IgM responses in vaccinated sera by ELISA and glycan microarray — supporting carbohydrate-conjugate and fully synthetic glycan vaccine immunogenicity assessment, adjuvant comparison, and humoral immune response kinetics analysis.

IHC & FC Validated Profile TACA expression on FFPE tumor tissue sections (IHC) and live cancer cells (FC) for biomarker discovery, tumor heterogeneity assessment, and patient stratification in glycan-targeted immunotherapy clinical trial design.

All products manufactured by AtaGenix Laboratories under ISO 9001 & ISO 13485 quality systems.

References

1. Hakomori SI. Tumor-associated carbohydrate antigens defining tumor malignancy: basis for development of anti-cancer vaccines. Adv Exp Med Biol. 2001;491:369-402. DOI

2. Danishefsky SJ, Shue YK, Chang MN, Wong CH. Development of Globo H cancer vaccine. Acc Chem Res. 2015;48(3):643-652. DOI

3. Pinho SS, Reis CA. Glycosylation in cancer: mechanisms and clinical implications. Nat Rev Cancer. 2015;15(9):540-555. DOI

4. Yu AL, Gilman AL, Ozkaynak MF, et al. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med. 2010;363(14):1324-1334. DOI